Abstract
Daily rifampicin in a single dose of 600 mg, combined with other drugs, usually streptomycin and isoniazid, was given to forty-nine patients for 3 months. It was planned to continue for another 15 months with twice-weekly rifampicin 1200 mg plus isoniazid 900 mg, but the high incidence of side effects led to cessation of the intermittent regimen when only two patients had completed 18 months.
Though there was no serious problem with daily treatment, eleven patients (22%) were unable to continue rifampicin on the intermittent regimen. In eight (16%) a pyrexial syndrome occurred. In one of these patients there was also temporary renal failure and in another, precipitous thrombocytopenia led to epistaxis and bleeding into the tongue and lips. Symptomless thrombocytopenia developed in two other patients, making three cases (6%) of thrombocytopenia in all.
In sixteen (33%) of the forty-nine patients antibodies to rifampicin were detected in the blood. Side-effects occurred in nine (56%) of these, including the three developing thrombocytopenia, but in only two (6%) of the thirty-three patients with no antibodies detected. This association of toxic reactions with antibodies is highly significant (P < 0·001).
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Blajchman M. A., Lowry R. C., Pettit J. E., Stradling P. Rifampicin-induced immune thrombocytopenia. Br Med J. 1970 Jul 4;3(5713):24–26. doi: 10.1136/bmj.3.5713.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Croft J. D., Jr, Swisher S. N., Jr, Gilliland B. C., Bakemeier R. F., Leddy J. P., Weed R. I. Coombs'-test positivity induced by drugs. Mechanisms of immunologic reactions and red cell destruction. Ann Intern Med. 1968 Jan;68(1):176–187. doi: 10.7326/0003-4819-68-1-176. [DOI] [PubMed] [Google Scholar]
- Grumbach F., Canetti G., Le Lirzin M. Rifampicin in daily and intermittent treatment of experimental murine tuberculosis, with emphasis on late results. Tubercle. 1969 Sep;50(3):280–293. [PubMed] [Google Scholar]
- Gyselen A., Verbist L., Cosemans J., Lacquet L. M., Prignot J., Simon-Pouthier F., Debrabandere R., Devriendt J. A cooperative study on rifampicin in original treatment of advanced pulmonary tuberculosis. Acta Tuberc Pneumol Belg. 1969;60(3):563–576. [PubMed] [Google Scholar]
- HARRIS J. W. Studies on the mechanism of a drug-induced hemolytic anemia. J Lab Clin Med. 1956 May;47(5):760–775. [PubMed] [Google Scholar]
- Larbaoui D., Chaulet P., Grosset J., Abderrahim K., Oussedik N., Coucke C., Benabdallah L. Le traitement intermittent de la "tuberculose chronique invétérée" par l'association rifampicine-éthambutol: résultats préliminaires d'une enquête contrôlée menée à Alger. Rev Tuberc Pneumol (Paris) 1970 Jun;34(4):559–566. [PubMed] [Google Scholar]
- Lees A. W., Asgher B., Hashem M. A., Sinha B. N. Jaundice after rifampicin. Br J Dis Chest. 1970 Apr;64(2):90–95. doi: 10.1016/s0007-0971(70)80034-1. [DOI] [PubMed] [Google Scholar]
- Lesobre R., Ruffino J., Teyssier L., Achard F., Brefort G. Les ictères au cours du traitement par la rifampicine (12 observations) Rev Tuberc Pneumol (Paris) 1969 Apr-May;33(3):393–403. [PubMed] [Google Scholar]
- Polansky F. Trial of sanatorium treatment including a comparison of standard and intermittent continuation chemotherapy: Central Bohemian Tuberculosis Services-WHO-British Medical Research Council investigation. Bull Int Union Tuberc. 1970 Jun;43:295–302. [PubMed] [Google Scholar]
- Poole G., Stradling P. Intermittent chemotherapy for tuberculosis in an urban community. Br Med J. 1969 Jan 11;1(5636):82–84. doi: 10.1136/bmj.1.5636.82. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Poole G., Stradling P. The long-term use of intermittent streptomycin plus isoniazid in the treatment of tuberculosis. Tubercle. 1965 Sep;46(3):290–293. doi: 10.1016/s0041-3879(65)80026-5. [DOI] [PubMed] [Google Scholar]
- Ramakrishnan C. V., Devadatta S., Evans C., Fox W., Menon N. K., Nazareth O., Radhakrishna S., Sambamoorthy S., Stott H., Tripathy S. P. A four-year follow-up of patients with quiescent pulmonary tuberculosis at the end of a year of chemotherapy with twice-weekly isoniazid plus streptomycin or daily isoniazid plus pas. Tubercle. 1969 Jun;50(2):115–124. doi: 10.1016/0041-3879(69)90018-x. [DOI] [PubMed] [Google Scholar]
- Stradling P., Poole G. W. Twice-weekly streptomycin plus isoniazid for tuberculosis. Tubercle. 1970 Mar;51(1):44–47. doi: 10.1016/0041-3879(70)90127-3. [DOI] [PubMed] [Google Scholar]
- Verbist L., Gyselen A. Antituberculous activity of rifampin in vitro and in vivo and the concentrations attained in human blood. Am Rev Respir Dis. 1968 Dec;98(6):923–932. doi: 10.1164/arrd.1968.98.6.923. [DOI] [PubMed] [Google Scholar]